Skip to main content

We at Fresenius are fully committed to acting with integrity and in compliance with the law. Reliability and responsibility, mutual trust and respect, fair working conditions, and a corporate culture characterized by integrity are inseparably linked to this for us, as is social and ecological sustainability. This includes respect for human rights and the protection of nature as the basis of life. Based on these values and standards, we create the necessary conditions to contribute to high-quality yet affordable healthcare. At Fresenius, the patient always comes first.

Reports on possible misconduct within our company and in our supply chain help us to live up to these standards. We follow up on these reports quickly and carefully in order to swiftly remediate violations and take measures – and to remediate grievances sustainably and effectively for the future. 

Please contact us if you have evidence of misconduct or a violation of laws, policies or other regulations related to our business operations. This applies regardless of whether you are an employee – including temporary workers – or a supplier, customer, patient, resident of one of our sites or any other potentially affected party. Representatives of NGOs can also contact us with their concerns. 

Reports can be submitted anonymously or by name at any time. We treat all reports confidentially and review every report carefully and comprehensively. At Fresenius, we protect all individuals who report on violations in good faith and/or support an investigation. This includes that we rigorously follow up on any cases of retaliation against such reporters. Furthermore, we investigate promptly any cases in which individuals – against their better judgement – falsely accuse others. 

To make it as easy as possible for potentially affected parties, we have launched a new and improved whistleblowing system: The Fresenius Integrity Line.This is an external grievance and whistleblowing system operated by an independent provider. It can be accessed via:
https://freseniusgroup.ethicspoint.com  

The Fresenius Integrity Line is a comprehensive and confidential reporting platform via which you can raise any issues or concerns you may have about ethics and compliance in our workplace. We want to work with you to prevent and stop fraud, abuse, any wrongdoing that could harm our company or our patients as well as any other misconduct in the workplace while cultivating a positive work environment.

With the new Fresenius Integrity Line we offer both our own employees and external stakeholders, who have business or other relations with Fresenius, various channels to express questions or concerns. Reporting via those channels is secure, confidential, and available anytime and anywhere.

You can submit reports via the Fresenius Integrity Line online or by phone call (the phone numbers for each country are listed on the platform), anonymously or with your name. Reports can also be easily submitted using your smartphone  or by scanning a QR code that we provide on the homepage of this new platform.

Information can also be sent to our functional e-mail addresses which have been set up especially for this purpose: 

Reports concerning the violation of human rights can be sent to: humanrights@fresenius.com   

Reports concerning any (other) Compliance violations: integrityline@fresenius.com
All other general questions to Risk & Integrity Team to: corporate-compliance@fresenius.com 
 
Reports in writing (letters) can also be addressed to:

Fresenius SE & Co. KGaA 
Business Integrity/ Group CMIO 
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
 
Employees and temporary workers employed by Fresenius' service providers can also contact the Fresenius Group CMIO-Team by e-mail, telephone or in person. You can find the relevant contacts on the Fresenius intranet.
 

You can report any violations of applicable laws and Fresenius-internal regulations using the reporting channels described above. These include, e.g., corruption, competition and antitrust violations, data protection violations, violations of employee rights, as well as accounting, finance and tax violations ("compliance violations"). In addition, you can report actual or potential violations of human rights or environmental obligations related to our business activities and our direct and indirect suppliers ("human rights violations"). 

In your report, please describe the facts of the case as clearly and in as much detail as possible. You can use the following questions as a guide: 
What?         Who?         When?         How?          Where? 

If you use these questions as a guidance, we will be able to process your report more easily. If you use our web-based reporting system, after a brief information and security prompt, you will be asked to indicate the focus area of your report and to provide information on the parties involved and the time period of the violation.

It is always helpful that you are available for further queries and clarification. If you are willing to do so, but still wish to remain anonymous, please use the option of the protected mailbox available to you in our web-based reporting system.
 

All reports are processed by specially trained employees of our Business Integrity Team. Depending on the circumstances, it may be necessary to involve other subject matter experts and functions to further clarify an incident. 

For the purpose of transparent communication, you will find below a description of the typical course of the procedure:
 

Verfahrensschritte Hinweisgeber Fresenius

  • Report intake and documentation
    As soon as your report is received in one of the channels described above, but at the latest after seven days, you will receive an acknowledgement of receipt. It may also be helpful to further process the matter together with you. E.g., in the case of human rights violations, consensual agreed solutions may be appropriate, depending on the severity and the issue.
  • Plausibility check and categorization of report
    As soon as it is determined that the received report falls within the scope of the procedure, the report will be carefully checked for plausibility and categorized in order to forward it to the responsible function where needed. If an investigation is not possible due to a lack of sufficient information we will try to contact you – if you have not submitted your report anonymously and without opening a secure channel of communication – to request further information. 
  • Fact finding
    We will examine the facts comprehensively and conscientiously. All reports will be investigated appropriately. In addition to obtaining background information – as far as possible – we will review documents, analyze data and conduct interviews. In addition, the investigation may also include discussing the facts with you and, if necessary, reaching a friendly settlement of the dispute.
  • Remediation
    If we have identified a violation, our top priority is to remediate it quickly. In addition, disciplinary measures can be taken to sanction individual misconduct and further process improvements can be implemented to avoid reoccurrence of the violation in the future. 
  • Review of the mitigating measures and the result
    In the case of human rights violations, we offer to evaluate the measures and achieved results together with you in order to find out whether they were or are effective or whether they need further improvement.

Fresenius commits itself and all employees involved in this process to handle all information professionally, independently and impartially, carefully and confidentially. 

In accordance with the principles of fair trial, all relevant circumstances of the case will be taken into account. In addition, the principle of proportionality must always be upheld. Accused persons are presumed innocent as long as the opposite has not been proven.

Our employees involved in the various process steps are experienced in dealing professionally with reports on violations and the underlying facts. They receive ongoing training on our processes and the relevant topics. In addition, they work on incoming reports independently of instructions. 

Reports on violations – and the underlying issues – can vary widely in their scope and complexity. It is therefore difficult to set a generally applicable timetable for investigations. However, we are committed to conducting and completing internal investigations as quickly and efficiently as possible.

After the conclusion of the procedure – at the latest after the expiry of three months after receipt of the report – and insofar as this does not jeopardize the investigation, you will receive a final summary and feedback on your report as well as on the measures taken, taking into account the applicable data protection regulations and other confidentiality requirements as well as safeguarding overriding company interests. 

In our Fresenius Code of Conduct and our Group-wide process descriptions, we have made clear that we will not tolerate any retaliation against employees who in good faith report possible or actual violations or support investigations. This protection is also served by our measures to maintain confidentiality ('need-to-know' principle) and strict rules for dealing with conflicts of interest. In the case of external reporters, we strive to achieve a comparable level of protection and have formulated corresponding expectations in our Code of Conduct for Business Partners.

A violation of this prohibition against retaliation may be reported and investigated under the same rules as described herein.

The results of our risk analysis and the findings on potential target groups of our grievance and whistleblower channels will be incorporated into the further development of our grievance and whistleblowing procedures and the processing of grievances and whistleblowing reports. Based on our findings, we will review the effectiveness of the procedure described above on an annual basis or more frequently if required. If necessary, we will make appropriate adjustments and changes with regard to the accessibility and process of the procedure. In order to continuously improve, we also welcome suggestions and feedback from whistleblowers.

As we always strive for transparency, we regularly publish information on the number of reports received, the topics, the conclusions drawn from the reports and the measures taken. This publication is always anonymous.

* The whistleblowing system can be used for reports concerning Fresenius Management SE, Fresenius SE & Co. KGaA and Fresenius Digital Technology. Please address reports for Fresenius Kabi, Fresenius Helios or Fresenius Vamed to the relevant business segment.

Contact

Fresenius SE & Co. KGaA
Business Integrity/ Group CMIO
Else-Kröner-Straße 1
61352 Bad Homburg
Germany

Contact concerning human rights:
humanrights@fresenius.com   

Contact for all other Compliance reports:
integrityline@fresenius.com

All other general Risk & Integrity topics:
corporate-compliance@fresenius.com

Whistleblowing system

Reports on possible human rights violations or other types of compliance violations can be reported around the clock, either anonymously or by name, via our whistleblower system*:


Phone number: +49 (0) 800 181 1338*
https://freseniusgroup.ethicspoint.com

* The prices of your mobile or landline contract apply 

January 09

January 09, 2023
San Francisco, USA

41st Annual JP Morgan Healthcare Conference

Fresenius Kabi expands its portfolio of critical care medicine by launching Lacosamide Injection, USP, a generic equivalent to VIMPAT® in the U.S. 

Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in the U.S. beginning today. 

* VIMPAT® is a registered trademark of UCB, Inc.

Fresenius Kabi expands its portfolio of critical care medicine by launching Lacosamide Injection, USP, a generic equivalent to VIMPAT® in the U.S. 

Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in the U.S. beginning today. 

* VIMPAT® is a registered trademark of UCB, Inc.

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has entered the Dow Jones Sustainability World Index. Additionally, the company has been included for the 13th time in the Dow Jones Sustainability Index (DJSI) Europe. Fresenius Medical Care achieved an improved rating in most of the evaluated categories, and was awarded maximum scores for its environmental and social reporting. The company was also awarded significantly higher scores in the areas of occupational health and safety, talent attraction and retention, and customer relationship management.

“To us, successful sustainability management means creating lasting economic, environmental and social value,” said Helen Giza, CEO of Fresenius Medical Care. “We are proud that the DJSI has recognized our efforts to integrate sustainable actions systematically into our company.”

To compile the Dow Jones Sustainability Indexes, the international financial services company S&P Global evaluates the environmental, social and economic performance of companies. The 10 percent of global companies with the highest evaluations form the DJSI World. The DJSI Europe index is composed of the top 20 percent of the companies headquartered in Europe.

You can find an overview of Fresenius Medical Care’s progress in sustainability here.
 

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Implementation of measures as presented herein may be subject to information & consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.

In this year's ranking, CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 680 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

The U.S. Food and Drug Administration (FDA) has approved Fresenius Kabi’s biosimilar Idacio®, a citrate-free formulation of adalimumab. Idacio® (adalimumab) is approved for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira®**. 

With Idacio Fresenius Kabi expands its U.S. biosimilars portfolio focused on immunology and oncology. It is the company’s second approved biosimilar in the U.S. launching from July 2023 in accordance with the relevant patent settlement agreement with Abbvie. 

* Idacio® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries
**Humira® is a registered trademark of AbbVie, Inc. 

 

In this year's ranking, CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 680 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

The U.S. Food and Drug Administration (FDA) has approved Fresenius Kabi’s biosimilar Idacio®, a citrate-free formulation of adalimumab. Idacio® (adalimumab) is approved for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira®**. 

With Idacio Fresenius Kabi expands its U.S. biosimilars portfolio focused on immunology and oncology. It is the company’s second approved U.S. biosimilar launching from July 2023 in accordance with the relevant patent settlement agreement with Abbvie. 


* Idacio® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries
**Humira® is a registered trademark of AbbVie, Inc.
 
 

Fresenius has been included again in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent of companies based on S&P Global’s analysis of their economic, environmental, and social performance. Fresenius achieved improvements in many categories, the most significant ones in the areas of Occupational Health and Safety, Climate Strategy, as well as Risk and Crisis Management. 

Subscribe to